Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12609000039280
Ethics application status
Approved
Date submitted
6/10/2008
Date registered
19/01/2009
Date last updated
19/01/2009
Type of registration
Retrospectively registered

Titles & IDs
Public title
A study of the structure of a newly identified hormone in the blood to help diagnose the cause of chest pain.
Scientific title
A study to determine the amino acid structure of plasma B-type Natriuretic Peptide signal peptide (BNP-SP) as a specific and early clinical biomarker of acute myocardial infarction in patients with chest pain.
Universal Trial Number (UTN)
Trial acronym
BNP Signal Peptide Stucture Study "SSS"
Linked study record

Health condition
Health condition(s) or problem(s) studied:
acute myocardial infarction 3792 0
Condition category
Condition code
Cardiovascular 3969 3969 0 0
Coronary heart disease

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Using specific immunoassay, peptide sequencing, mass spectrometry, high performance liquid chromatography (HPLC), we will determine the amino acid structure of plasma B-type Natriuretic Peptide signal peptide (BNP-SP). A single 50ml blood sample will be collected at admission from people who present to hospital within 8 hours of onset of symptoms with evidence of an acute myocardial infarction. This study is limited to the collection of a single blood sample only and will continue until 70 samples of 50 mls each have been collected.
Intervention code [1] 3510 0
Early detection / Screening
Comparator / control treatment
uncontrolled
Control group
Uncontrolled

Outcomes
Primary outcome [1] 4873 0
The primary outcome of this study will be the identification on brain natriuretic peptide signal peptide (BNP-SP) amino acid structure. Using specific immunoassay, peptide sequencing, mass spectrometry, high performance liquid chromatography (HPLC), we will determine the amino acid structure of plasma B-type Natriuretic Peptide signal peptide (BNP-SP).
Timepoint [1] 4873 0
One blood sample of 50mls taken within 8 hours of onset of symptoms of a heart attack
Secondary outcome [1] 8221 0
n/a
Timepoint [1] 8221 0
n/a

Eligibility
Key inclusion criteria
70 patients presenting to the Accident & Emergency department or the Coronary Care Unit of Christchurch Hospital with typical chest pains (<8 hours from onset), clear evidence of "ST" segment elevation on Electrocardioegraph (ECG) together with a rise of plasma Troponin levels
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Unable to give informed consent Unable to comply with study requirements

Study design
Purpose
Screening
Duration
Cross-sectional
Selection
Defined population
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
9/01/2008
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
70
Accrual to date
Final
Recruitment outside Australia
Country [1] 1247 0
New Zealand
State/province [1] 1247 0

Funding & Sponsors
Funding source category [1] 3976 0
Government body
Name [1] 3976 0
Health Research Council of New Zealand
Country [1] 3976 0
New Zealand
Primary sponsor type
Government body
Name
Health Research Council of New Zealand
Address
PO Box 5541, Wellesley Street, Auckland, 1141, New Zealand
Country
New Zealand
Secondary sponsor category [1] 3565 0
None
Name [1] 3565 0
Address [1] 3565 0
Country [1] 3565 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 6125 0
Upper South B Regional Ethics Committee
Ethics committee address [1] 6125 0
Ethics committee country [1] 6125 0
New Zealand
Date submitted for ethics approval [1] 6125 0
Approval date [1] 6125 0
15/01/2007
Ethics approval number [1] 6125 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 29006 0
Address 29006 0
Country 29006 0
Phone 29006 0
Fax 29006 0
Email 29006 0
Contact person for public queries
Name 12163 0
Lorraine Skelton
Address 12163 0
Department of Medicine
University of Otago
Christchurch School of Medicine and Health Sciences
PO Box 4345
Christchurch 8140
Country 12163 0
New Zealand
Phone 12163 0
+643 364 1063
Fax 12163 0
+643 364 1115
Email 12163 0
lorraine.skelton@cdhb.govt.nz
Contact person for scientific queries
Name 3091 0
Dr Chris Pemberton
Address 3091 0
Department of Medicine
University of Otago
Christchurch School of Medicine and Health Sciences
PO Box 4345
Christchurch 8140
Country 3091 0
New Zealand
Phone 3091 0
+643 364 0887
Fax 3091 0
+943 364 0818
Email 3091 0
chris.pemberton@otago.ac.nz

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.